Synthetic lethality - based strategy has been developed to identify therapeutic targets in cancer
harboring tumor suppressor gene mutations, as exemplified by the effectiveness of PARP inhibitors in BRCA1 / 2 - mutated tumors.
These three chromosome arms
harbor well - known oncogenes and
tumor suppressor genes that have been shown to undergo copy number alterations in many cancers, including BC (Vogelstein et al., 2013).